Automate Your Wheel Strategy on CERT
With Tiblio's Option Bot, you can configure your own wheel strategy including CERT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CERT
- Rev/Share 2.5215
- Book/Share 6.653
- PB 1.6925
- Debt/Equity 0.2876
- CurrentRatio 2.1573
- ROIC 0.0106
- MktCap 1808626240.0
- FreeCF/Share 0.6442
- PFCF 17.4468
- PE 227.0285
- Debt/Assets 0.1995
- DivYield 0
- ROE 0.0075
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | CERT | Morgan Stanley | -- | Equal Weight | -- | $16 | July 3, 2025 |
| Upgrade | CERT | Barclays | Equal Weight | Overweight | -- | $14 | May 8, 2025 |
| Initiation | CERT | TD Cowen | -- | Buy | -- | $16 | Feb. 27, 2025 |
| Upgrade | CERT | UBS | Neutral | Buy | -- | $16 | Sept. 27, 2024 |
News
Certara, Inc. (CERT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Certara, Inc. (NASDAQ:CERT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley, Research Division Presentation Craig Hettenbach VP & Equity Analyst All right. I think we're on time here.
Read More
Certara, Inc. (CERT) Presents At Baird Global Healthcare Conference 2025 (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Certara, Inc. (NASDAQ:CERT ) Baird Global Healthcare Conference 2025 September 9, 2025 10:15 AM EDT Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Joseph Vruwink - Robert W. Baird & Co. Incorporated, Research Division Presentation Joseph Vruwink Senior Research Analyst All right.
Read More
Cerrado Gold Inc. (CRDOF) Q2 2025 Earnings Call Transcript
Published: August 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Cerrado Gold Inc. (OTCQX:CRDOF) Q2 2025 Earnings Conference Call August 25, 2025 11:00 AM ET Company Participants Michael McAllister - Vice President of Investor Relations Mark Peter Brennan - CEO & Chairman Jason Brooks - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. This is the conference operator.
Read More
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3 Momentum Stocks That Could Soar Post-Market Volatility
Published: April 21, 2025 by: MarketBeat
Sentiment: Negative
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
Read More
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Published: April 14, 2025 by: Benzinga
Sentiment: Positive
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.
Read More
Buy Certara After The FDA Announcement
Published: April 11, 2025 by: Seeking Alpha
Sentiment: Positive
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials.
Read More
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Published: April 11, 2025 by: Benzinga
Sentiment: Neutral
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Read More
Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc. Michael Cherny - Leerink Partners Christine Rains - William Blair David Windley - Jefferies Constantine Davides - Citizens Securities Andrew Moss - Bank of America Kyle Crews - UBS Operator Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2024 Earnings Conference Call.
Read More
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Certara, Inc. (CERT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.
Read More
About Certara, Inc. (CERT)
- IPO Date 2020-12-11
- Website https://www.certara.com
- Industry Medical - Healthcare Information Services
- CEO William F. Feehery
- Employees 1487